2020-08-11@06:12:58 GMT
541 results - (0.001 seconds)

COVID 19 vaccine:

    The singer again shared his position on vaccines that seek to combat the Coronavirus Miguel Bosé. Photo: Archive / Reform Agency The singer Miguel Bosé He returned to the center of controversy with his controversial position regarding a future vaccine for the coronavirus, towards which he was apparently against. A Twitter user shared a graph that showed the relationship between flu vaccinated and those killed by Covid-19, suggesting that mortality increases if the number of vaccinated increases. “THEY WANT TO KILL US !!!“, wrote Bosé by sharing the tweet. THEY WANT TO KILL US !!! https://t.co/l5W4sAGvkb – Miguel Bosé (@BoseOfficial) August 9, 2020 This is not the first time that the famous one speaks against the...
    SAN FRANCISCO (KGO) -- The race to develop a vaccine for the coronavirus is not only shifting into high gear. It turns out, drug companies are following different maps to find the finish line."The most important thing in a vaccine is the idea," says UCSF professor Dr. Jay Levy, M.D.Levy is tracking efforts worldwide, including the roughly half-dozen domestic vaccine trials now getting underway in the United States.VIDEO: Here's what goes into creating vaccine for COVID-19EMBED More News Videos The novel coronavirus is likely going to be with us until a vaccine is developed. What does it take to create a COVID-19 vaccine? He says one of the most intriguing is by the company Moderna, which is using a new...
    (CNN) — Safety will not be compromised for a Covid-19 vaccine, the US Food and Drug Administration commissioner said Monday. Dr. Stephen Hahn made the declaration in a video briefing with the American Medical Association. More than 5 million Americans have been infected with coronavirus, and more than 163,000 have died, according to Johns Hopkins data. Hahn acknowledged that because of the speed with which the agency is working, some experts have questioned whether the FDA will compromise its scientific principles in reviewing clinical trial data. “Let me assure you that we will not cut corners,” Hahn said. “All of our decisions will continue to be based on good science and the same careful deliberative processes we have always used when reviewing...
    Good news for the start of these tests of a coronavirus vaccine. The vaccine they will be testing is the one being developed by the University of Oxford. Dr. Larry Bush, an epidemiologist, says that “This is the vaccine test that both in medical journals and in the press is having positive results.” Barry Snyder, a volunteer to receive trial vaccine, says that “At 75 years of age I told my wife we ​​have the opportunity to make a difference that does not happen often.” Dr Bush points out that the vaccine they use is a cold virus, which triggers an immune response in one of the proteins that the COVID-19 virus uses to attack the lungs. ...
    By Amir Vera, Holly Yan and Christina Maxouris | CNN Safety will not be compromised for a Covid-19 vaccine, the US Food and Drug Administration commissioner said Monday. Dr. Stephen Hahn made the declaration in a video briefing with the American Medical Association. More than 5 million Americans have been infected with coronavirus, and more than 163,000 have died, according to Johns Hopkins data. Hahn acknowledged that because of the speed with which the agency is working, some experts have questioned whether the FDA will compromise its scientific principles in reviewing clinical trial data. “Let me assure you that we will not cut corners,” Hahn said. “All of our decisions will continue to be based on good science and...
    SAN ANTONIO – Editor’s note: This content was created exclusively for KSAT Explains, a new, weekly streaming show that dives deep into the biggest issues facing San Antonio and South Texas. Watch past episodes here and download the free KSAT-TV app to stay up on the latest. Research is being done around the globe in the search for a COVID-19 vaccine. And some critically important clinical trials are happening here in San Antonio. But what makes our city so well-positioned to host these trials?A Strong Research CommunityHeather Hanson, the president of BioMed SA, admits that a lot of people see San Antonio as a small place in the life science community. But Hanson is working to change that perception. BioMed...
    Gilead Sciences on Monday applied for approval from the U.S. Food and Drug Administration for its COVID-19 treatment, remdesivir. The biotech company also said the antiviral drug will go by the brand name of Veklury in the U.S. "Today's filing is an important milestone as we continue to partner with the U.S. government and health care authorities around the globe to address the treatment needs of patients with COVID-19," said Merdad Parsey, Gilead's chief medical officer, in a statement.  Remdesivir is available in the U.S. on an emergency basis for hospitalized patients with severe cases of COVID-19, but FDA approval of Gilead's new drug application would clear the way for wider use of the treatment. Remdesivir has already been approved...
    SAN FRANCISCO -- Novel coronavirus is likely going to be with us until a vaccine is developed. We know that COVID-19 attaches to your cells through your mouth and nose and works its way into your lungs where it can spread to other parts of your body. How do we stop it from doing that? With a vaccine. So what does it take to create one?"A vaccine is a way for your immune system to identify a foreign invader and prepare for an attack even before you have an infection," said ABC7 News special correspondent Dr. Alok Patel.A vaccine can stop a virus in its tracks, keeping you from getting sick."What scientists around the world are trying to do is...
    SAN FRANCISCO -- Novel coronavirus is likely going to be with us until a vaccine is developed. We know that COVID-19 attaches to your cells through your mouth and nose and works its way into your lungs where it can spread to other parts of your body. How do we stop it from doing that? With a vaccine. So what does it take to create one?"A vaccine is a way for your immune system to identify a foreign invader and prepare for an attack even before you have an infection," said ABC7 News special correspondent Dr. Alok Patel.A vaccine can stop a virus in its tracks, keeping you from getting sick."What scientists around the world are trying to do is...
    DUBAI (Reuters) - Chinese state-owned pharmaceutical company Sinopharm has begun Phase III clinical trials of a COVID-19 vaccine in Bahrain, after launching similar trials in the United Arab Emirates last month, Bahrain's health ministry said on Monday. The human trial, which launched in the UAE capital Abu Dhabi in mid-July, is a partnership between Sinopharm’s China National Biotec Group (CNBG) and Abu Dhabi-based artificial intelligence and cloud computing company Group 42 (G42). G42 Healthcare CEO Ashish Koshy said expanding the trial to the small island state of Bahrain will increase the numbers of participants on a par with trials underway in nations with much larger populations. The study, which uses an inactivated vaccine, will include around 6,000 citizens and resident...
    Fact check: U.S. GDP drop in 2020s second quarter is the worst in modern history Dollar Tree, Family Dollar reverse decision to require masks at all stores, but request customers wear them Russian Covid-19 Vaccine Is ‘Pandora’s Box,’ Industry Body Warns (Bloomberg) -- Russia’s race to allow civilian use of a potential coronavirus vaccine before clinical trials are complete could put people at risk, according to a local association of multinational pharmaceutical companies. © Bloomberg An anesthesiologist inspects medical equipment monitoring a patient with Covid-19 at a hospital in Moscow on May 13. The government plans to give a vaccine developed by Moscow’s Gamaleya Institute conditional registration as early as this week, which would open the door to civilian...
    Any coronavirus vaccine developed in the United States would be shared with the international community only after the needs of Americans have been met, Health and Human Services Secretary Alex Azar told reporters on Monday during his visit to Taiwan, the Independent reported. “Our first priority, of course, is to develop and produce enough quantity of safe and effective FDA-approved vaccines and therapeutics for use in the United States,” Azar said. “But we anticipate having capacity that, once those needs are satisfied, those products would be available in the world community according to fair and equitable distributions that we would consult in the international community on.” President Donald Trump has vowed to have a vaccine ready before the end of...
    More than a third of Americans said they would not get a vaccine against coronavirus at the present time even if it were to be free and approved by the FDA.  65% of those responding to the survey say they would accept the offer and get themselves vaccinated while 35% said they would not.  Those who who say they would not be happy to get the injection also runs roughly along party political lines with less than half of Republicans (47%) saying they would take the jab but with 81% of Democrats ready to line up to be inoculated, according to a new Gallup poll.  35% of Americans say they would not take COVID injection when its available according to...
    DUBAI (Reuters) - Saudi Arabia will soon begin Phase III clinical trials on around 5,000 people for a COVID-19 vaccine developed by China's CanSino Biologics Inc, a Saudi health ministry spokesman said on Sunday. Last month, CanSino's co-founder said the company was in talks with Russia, Brazil, Chile and Saudi Arabia to launch a Phase III trial of the vaccine candidate, Ad5-nCOV. The vaccine uses a harmless cold virus known as adenovirus type-5 (Ad5) to carry genetic material from the coronavirus into the body. Researchers said last month that CanSino's vaccine, co-developed with China's military research unit, appeared to be safe and induced immune responses in most subjects. Saudi Arabia plans to test the vaccine alongside a placebo on 5,000...
    Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases for the last three decades and an expert on pandemics for the last four decades, has been optimistic on a vaccine arriving at the end of 2020 or in early 2021, but he has also cautioned the public on their expectations for the effectiveness of any vaccine that is developed. “The chances of it being 98% are not great, which means you must never abandon the public-health approach,” Fauci told a recent live streamed Q&A hosted by Brown University. “You’ve got to think of a vaccine as a tool to be able to get a pandemic to no longer be a pandemic, but to be something that’s well-controlled.”...
    Bangkok, Aug 8 (EFE) .- Singapore begins the first phase of human testing of a new vaccine against COVID-19 and it is expected that it will be administered to about one hundred people next week in a first phase that will be extended until October. The new vaccine, which has received the name of Lunar-Cov19, is being developed by the School of Medicine of the National University of Singapore and the American pharmaceutical company Arcturus Therapeutics, reports this Saturday the Singaporean newspaper The Straits Times. At the moment, there are 26 vaccines worldwide that are being tested in humans or have received authorization to do so, while there are another 139 in research phases prior to experimentation with people. Singapore...
    The United States set a record for coronavirus cases on Saturday, with more than 5 million people now infected, according to a Reuters tally, as the country’s top infectious diseases official offered hope earlier this week that an effective vaccine might be available by year-end. With one out of every 66 residents infected, the United States leads the world in COVID-19 cases, according to a Reuters analysis. The country has recorded more than 160,000 deaths, nearly a quarter of the world’s total. The grim milestone comes as President Donald Trump signed executive orders intended to provide economic relief to Americans hurt by the coronavirus pandemic after the White House failed to reach a deal with Congress. On Friday, the...
    It’s encouraging that so many biotech and pharmaceutical companies are working on COVID-19 vaccines. Researchers will need a lot of volunteers to run human trials. Maybe you should participate. Arlene Weintraub profiles the type of person vaccine developers want for trials, along with what to expect if you participate, the chance of getting a placebo and possible side effects. Record-low mortgage rates Jacob Passy describes what should be a borrower’s paradise, but is turning out to be a difficult market for home buyers. A mural outside Andy's Bar, one of dozens of murals painted on buildings in Denton, Texas. Victoria DeCuir/ Courtesy Denton Public Library Retirement destinations Silvia Ascarelli helps a woman who wants to retire and move from...
    DR Anthony Fauci said on Friday that the chances of scientists creating a highly-effective vaccine to combat COVID-19 are slim. “The chances of it being 98 percent effective is not great,” Fauci said at a Q&A with the Brown University School of Public Health in Rhode Island. 4Dr Anthony Fauci said the chances of a coronavirus vaccine being highly-effective are slimCredit: Getty - Pool Fauci said scientists are hoping for a coronavirus vaccine that is at least 75 percent effective, but 50 percent or 60 percent would be acceptable. “Which means you must never abandon the public health approach,” the director of the National Institute of Allergy and Infectious Diseases explained. “You’ve got to think of the vaccine as a...
    WHITE HOUSE - U.S. President Donald Trump is predicting a COVID-19 vaccine might be ready by this year’s election, less than 90 days away.   “I’m optimistic that it’ll probably be around that date,” Trump told reporters on the White House South Lawn on Thursday.   “It wouldn’t hurt” his reelection chances to have the vaccine available by the November 3 election, acknowledged the president. “I’m doing it not for the election. I want it fast because I want to save a lot of lives.”   The scientific community, including prominent infectious disease experts such as Dr. Anthony Fauci, who is member of the White House coronavirus task force, however, expects that none of the numerous vaccine candidates now undergoing...
    President Trump says he's "optimistic" that a vaccine will be ready around Election Day, and it "wouldn't hurt" his chances against former Vice President Joe Biden. But having a vaccine available for widespread public use before 2021 is unrealistic, according to public health experts, including the Coronavirus Task Force's Dr. Anthony Fauci.  Mr. Trump told Geraldo Rivera's radio program "Geraldo in Cleveland," on WTAM, Thursday that a vaccine could "in some cases" be ready sooner than November 3, but "right around that time." Asked about this on the White House South Lawn a couple hours later, the president said he's "optimistic" about a vaccine being ready around that date. "I'm optimistic that it'll be probably around that date. I believe...
    Nurse Kath Olmstead prepares a shot as the world’s biggest study of a possible COVID-19 vaccine, developed by the National Institutes of Health and Moderna Inc., gets underway Monday, July 27, 2020, in Binghamton, N.Y. (AP Photo/Hans Pennink) As scientists continue to work on a COVID-19 vaccine, experts say the development may not include another widespread American health issue: obesity. READ MORE: Dr. Anthony Fauci says a coronavirus vaccine may be coming in 2021 CNN Health reports a coronavirus vaccination will likely follow the path of the shots developed for influenza, hepatitis B, tetanus and rabies in being less effective in obese adults. In turn, it will leave them more vulnerable to infection and illness. A health care...
    SAN ANTONIO – Editor’s note-- This video contains extended interviews and bonus footage not seen on-air. It was created specifically for the KSAT-TV streaming app. Download it today on your Apple TV, Amazon Fire Stick, Roku, Samsung smart TV and smart phone for more exclusive content. The race for a COVID-19 vaccine is global with more than 150 in development across the world. According to the World Health Organization, there are 42 companies working on a vaccine in the United States and two of them are in San Antonio: Pfizer and Moderna. There are four phases vaccines must go through before being considered for approval by the Food and Drug Administration: Preclinical: where the vaccine is tested on animals...
    Some medical workers and government employees in Moscow have been invited to receive what Russia says is the world’s first COVID-19 vaccine, which has been deemed to be safe after passing clinical trials, according to a report. At least one hospital is preparing lists of workers who want to be inoculated with the drug developed by Moscow-based Gamaleya Institute, a doctor who received an invitation told Bloomberg News. A city government official said that similar invitations for volunteers to receive the vaccination had been sent out to staffers, according to Bloomberg, which reported that it had seen one of the letters. The Moscow City Government’s press service declined to comment to the outlet. The Gamaleya vaccine, which was developed with...
    By Francesco Guarascio and Josephine Mason BRUSSELS/LONDON (Reuters) - The frenetic race to develop a COVID-19 vaccine has intensified safety concerns about an inoculation, prompting governments and drugmakers to raise awareness to ensure their efforts to beat the coronavirus aren't derailed by public distrust. There are more than 200 COVID-19 vaccine candidates in development globally, including more than 20 in human clinical trials. U.S. President Donald Trump has vowed to have a shot ready before year's end, although they typically take 10 years or longer to develop and test for safety and effectiveness. In the drive to find a potential COVID-19 vaccine "fast is good for politicians," said Heidi Larson, who leads the Vaccine Confidence Project (VCP), a global surveillance...
    Sign up for our COVID-19 newsletter to stay up-to-date on the latest coronavirus news throughout New York City BY ROXANNE LIU AND LUDWIG BURGER Shenzhen Kangtai Biological Products will produce AstraZeneca Plc’s potential COVID-19 vaccine in mainland China, the British drugmaker said on Thursday, its first deal to supply one of the world’s most populous countries. The deal underscores Astra’s frontrunner position in a global race to deliver an effective vaccine, given that Chinese ventures are leading at least eight of the 26 global vaccine development projects currently testing on humans. Under the agreement Shenzhen Kangtai, one of China’s top vaccine makers, will ensure it has annual production capacity of at least 100 million doses of the experimental shot...
    President TrumpDonald John TrumpLincoln Project ad dubs Jared Kushner the 'Secretary of Failure' Pence: Chief Justice Roberts 'has been a disappointment to conservatives' Twitter bans Trump campaign until it deletes tweet with COVID-19 misinformation MORE on Thursday said he thinks it's possible there will be a COVID-19 vaccine ready around Election Day in November. "I think in some cases, yes, possible before, but right around that time," Trump said on Geraldo Rivera's radio show when asked if he thought a vaccine would be ready by Nov. 3. "We have great companies," he added. "The rest of the world is also doing vaccines, so let's see how they do." The president's comments are likely to fuel concerns that he is exerting political...
    JERUSALEM (Reuters) - An Israeli research institute that is overseen by the Defence Ministry intends to begin human trials for a potential COVID-19 vaccine as early as October, Defence Minister Benny Gantz said on Thursday. The Israel Institute of Biological Research (IIBR) would start the trials in conjunction with the Health Ministry after a series of Jewish holidays ends in October, Gantz said. The IIBR has been working on a vaccine for six months and began animal trials in March. "All the initial experiments that have been successful ... give great hope," Gantz said after touring the institute in Ness Ziona, about 25 km (15 miles) south of Tel Aviv. Shmuel Shapira, the IIBR's director, said: "There is an excellent...
    SAN ANTONIO – We have been living with COVID-19 for the better part of 2020. The virus has infected millions of people, killed hundreds of thousands around the world and upended our daily lives. Many people believe life will return to normal with a vaccine. It’s not that simple. SMART. IN-DEPTH. LOCAL: CLICK HERE FOR MORE EPISODES OF KSAT EXPLAINS In this week’s episode of KSAT Explains, which can be streamed in the video player above, we examine the challenges to create a potential vaccine, how they are tested and how long it takes before a vaccine can safely be introduced into the general population. According to The New York Times, there are more than 165 COVID-19 vaccine trials underway....
    By Roxanne Liu and Tony Munroe BEIJING (Reuters) - Shenzhen Kangtai Biological Products will produce AstraZeneca Plc's potential COVID-19 vaccine in mainland China, the British drugmaker said on Thursday, its first deal to supply one of the world's most populous countries. To meet market demand in China, Shenzhen Kangtai will ensure it has annual production capacity of at least 100 million doses of the experimental shot AZD1222, which AstraZeneca co-developed with researchers at Oxford University, by the end of this year, AstraZeneca said. It must have capacity to produce at least 200 million doses by the end of next year as part of the exclusive framework agreement, its statement on the Chinese social media site WeChat added. The two companies...
    In late April, Southern weekender destination Savannah, Georgia, was bracing for a post-lockdown “flood of tourists”—and with it, a subsequent surge in coronavirus cases. At that point, the county’s percentage of positive test results hovered around 2 percent. By the end of June, as long cooped-up travelers poured into the city from all along the Eastern Seaboard, the city’s percentage-positive rate nearly quadrupled, and in an attempt to re-flatten the curve, Savannah’s Mayor Van Johnson issued an executive mask mandate.  "Savannah is experiencing thousands of visitors on our streets, in our establishments and most of them are not wearing face coverings,” Johnson wrote in a letter to Georgia’s notoriously mask mandate-averse governor Brian Kemp. “Infection numbers have exploded over the...
    (CNN)The US government is pouring billions into Covid-19 vaccines, and candidates from three companies are moving along quickly: Moderna, Pfizer and Novavax.Here's what you need to know about them.These are among the dozens of Covid-19 vaccines in trials around the world as researchers rush to find a way to stop the pandemic. To help speed the process, the US government's Operation Warp Speed is providing some funding for those three and five others -- vaccine candidates the US Department of Health and Human Services calls "the most promising."Operation Warp Speed's goal is to have 300 million doses of a vaccine that's safe and effective by January 2021.Read MoreWhile the Phase 1 trial results are promising, the proof will be in...
    (CBS DETROIT) – Victor McFadden is playing a crucial role in helping scientist find a solution for Covid-19. The 64-year-old is a volunteer for the phase three trial of merdona, a vaccine study headed by the national institutes of health. “Right now it’s whatever it takes to get this under control. I’m willing to help. I didn’t think i would do it like this but whatever it takes,” McFadden. The Henry Ford Health System kicked-off the human trial in Detroit as the only site in Michigan participating in the double-blind study. “One of the reasons we’re selected for this study is because we have a diverse patient population including a very diverse ethnic and racial groups that we can...
    by Melissa Hawkins, American University Researchers from the Centers for Disease Control and Prevention and other institutions recently published a study which estimated that the true number of people infected by COVID-19 could be six to 24 times higher than the number of confirmed cases. Melissa Hawkins, professor of public health at American University, explains what this large undercount means and why insufficient data is hampering the U.S.‘s ability to control the pandemic. What are some reasons for the large disparity between the true number of infected cases and the confirmed case count in the U.S.? We just passed 4 million total confirmed cases and over 150,000 deaths. But those confirmed cases really only tell part of the story...
    SAN FRANCISCO (KGO) -- Brace for another wave of coronavirus. That's the message from a top epidemiologist at UCSF.While some experts say California is still in the first wave of coronavirus cases, UCSF's head of disease and global epidemiology Dr. George Rutherford told reporters Wednesday that a "third wave" -- or surge -- of cases is essentially inevitable.RELATED: Interactive COVID-19 map shows chance someone has virus near you"I don't think we'll get back to a true baseline before we see a third wave," Dr. George Rutherford, UCSF's head of disease and global epidemiology, told reporters Wednesday. "We'll probably see it go back down a little bit before it starts to go back up again."Rutherford said California appears to be at...
    Scientists suspect that a potential COVID-19 vaccine would be less effective in protecting obese Americans from the disease, which has infected millions worldwide and killed more than 157,000 in the U.S. alone. In a  new report from CNN and Kaiser Health News, researchers pointed out that other prominent vaccines dating back to 1985 -- like those for the flu and hepatitis A and hepatitis B -- have not worked as well in providing immunity for obese adults. “Will we have a COVID vaccine next year tailored to the obese? No way,” Raz Shaikh, an associate professor with the University of North Carolina’s nutrition department, told Kaiser on Wednesday. RUSSIA PLANS MASS VACCINATIONS BY OCTOBER That said, those with obesity are still highly encouraged to obtain...
    Wednesday, Health and Human Services Secretary Alex Azar discussed a coronavirus vaccine, saying it is “realistic” to have one in the fall and millions of doses available for distribution by the end of 2020. Azar on Fox News Channel’s “America’s Newsroom” praised President Donald Trump’s leadership in developing a vaccine, saying the United States has made “the most historic advances in the development of vaccines we have ever seen in human history.” He added that is is “very credible” to expect tens of millions of doses of a vaccine by the end of the year and hundreds of millions at the beginning of next year. “Well, let me talk about vaccine, because this has just been the last two weeks....
    Brett Favre believes in CBDs future in NFL, partners with Green Eagle The 14 Smartest Desks for the Smallest of Spaces 5 Large Biotech and Pharma Stocks Are Dirt Cheap, and Not Because of COVID-19 The biopharmaceutical industry has been one of the most resilient in dealing with the coronavirus pandemic. While the Dow Jones industrial average and S&P 500 have struggled to get back to even for the year, the Nasdaq is hitting record high after record high. Two contributing factors are in play, health care stocks and big tech. It’s no secret that Amazon, Apple and Facebook have been a huge contributing factor of the recovery for the broad markets, by the sheer weighting of the S&P...
    SAN FRANCISCO (KGO) -- The outbreak of COVID-19 is having a major impact across the world but also in cities across Northern California. A shelter-in-place has been issued in the Bay Area, along with a similar order statewide.The latest number of confirmed cases in the U.S. can be found at the CDC's 2019 Novel Coronavirus in the U.S. page. (The CDC updates the webpage on Monday, Wednesday and Friday.)Join anchor Kristen Sze for ABC7's new daily, interactive newscast about the novel coronavirus outbreak in the Bay Area and around the world. You can check here to stream the show Monday-Friday at 3 p.m. GET HELP: Resources and information about COVID-19 COVID-19 RISK CALCULATOR: Quiz yourself on the safest, most...
    Sign up for our COVID-19 newsletter to stay up-to-date on the latest coronavirus news throughout New York City BY ANKUR BANERJEE AND CARL O’DONNELL Moderna Inc said on Wednesday smaller volume agreements for its experimental coronavirus vaccine have been priced in the range of $32 to $37 per dose, higher than the price set by the U.S. deal for Pfizer Inc’s vaccine candidate. As the race to develop COVID-19 vaccines reach a decisive stage, with several candidates being tested in pivotal late-stage studies, pricing has come under increasing scrutiny. “We will be responsible on price well below (its) value during the pandemic,” Chief Executive Officer Stéphane Bancel said on a conference call, adding that larger volume agreements for its...
    New York, Aug 5 (EFE) .- Wall Street opened this Wednesday in green and the Dow Jones Industrials, its main indicator, advanced 0.73% due to hopes of developing a vaccine against COVID-19, the expectation of a new stimulus package in the US and the good results of Disney. Five minutes after the start of operations on the New York Stock Exchange, the Dow Jones rose 196.05 points, to 27,024.52, while the selective S&P 500 rose 0.43% or 14.14 integers, to 3,320 , 65. For its part, the Nasdaq market composite index, where the main technology companies are listed, gained 0.69% or 11.55 units, up to 10,958.88 points, a new intraday record. The New York parquet was thus opening with profits,...
    FARGO, N.D. (AP) — A medical research company in Fargo will conduct two clinical trials that could lead to a vaccine for COVID-19. Lillestol Research is among several facilities across the nation participating in “Operation Warp Speed,” the federal government’s plan to provide 300 million doses of coronavirus vaccine by January 2021. Lillestol operations director Jamie Brown says the company plans to begin recruiting patients for the trial soon. She says patients chosen for the study will be tracked regularly to see if they contract coronavirus, KFGO reported. Participants will be compensated, but the company did not say to what extent. “These trials are placebo-controlled, meaning patients will get real vaccine or a placebo, which is inactive. We won’t know...
    As Covid-19 cases and deaths continue an upward trajectory in the United States, a watchdog group and allied scientists Tuesday urged the federal government and Gilead, the maker of the promising drug remdesivir, to explain why they have not pursued a similar treatment that might be cheaper for consumers though possibly less profitable to the company. The drug in question, known as GS-4441524, closely resembles remdesivir in chemical makeup, Public Citizen and scientist co-signers wrote in a joint letter to Gilead and United States federal government agencies including the National Institutes of Health, the National Institute of Allergy and Infectious Diseases, the U.S. Food and Drug Administration, and Biomedical Advanced Research and Development Authority. Specifically, Public Citizen et al noted that GS-4441524: Has...
    BERLIN (Reuters) - Germany's BioNTech and China's Shanghai Fosun Pharmaceutical on Wednesday announced the start of another COVID-19 vaccine trial in China with a total of 144 participants. "The study is designed to support the regulatory approval process for the Chinese market and intends to confirm that the safety and immunogenicity profile observed in participants from the German and U.S. trials is comparable to that of Chinese participants," BioNTech said in a statement. (Reporting by Thomas Seythal; Editing by Michelle Martin) Copyright 2020 Thomson Reuters.
    (Kaiser Health News)For a world crippled by the coronavirus, salvation hinges on a vaccine.But in the United States, where at least 4.6 million people have been infected and nearly 155,000 have died, the promise of that vaccine is hampered by a vexing epidemic that long preceded Covid-19: obesity.Sedentary lockdowns put kids at risk for obesity. Heres how to help them stay movingScientists know that vaccines engineered to protect the public from influenza, hepatitis B, tetanus and rabies can be less effective in obese adults than in the general population, leaving them more vulnerable to infection and illness. There is little reason to believe, obesity researchers say, that Covid-19 vaccines will be any different."Will we have a Covid vaccine next year...
    BENGALURU (Reuters) - India's Zydus Cadila said on Wednesday its COVID-19 vaccine candidate was found to be safe and well-tolerated in an early-stage human trial. The company will now start a mid-stage trial of the vaccine candidate, ZyCoV-D, in over 1,000 healthy adult volunteers from Thursday to test its effectiveness, it said in a regulatory filing. Zydus plans to complete late-stage trials for ZyCoV-D by February or March and could produce up to 100 million doses a year initially, the company's chairman told Reuters last month. The safety of the vaccine candidate in volunteers enrolled in the early-stage trial, who were administered doses since July 15, was endorsed by an independent data safety monitoring board. Zydus is also among the...
    GAITHERSBURG, Md. (WJZ) — Novavax, a Gaithersburg-based biotech company, announced Tuesday encouraging results from its potential COVID-19 vaccine. The Phase 1 portion of the Phase 1/2 clinical trial evaluated two doses of Novavax’ COVID-19 vaccine across two dose levels in 131 healthy adults ages 18-59 years. NVX‑CoV2373, the company’s recombinant COVID-19 vaccine candidate adjuvanted with Matrix-M, was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera, researchers said. CORONAVIRUS COVERAGE: TIMELINE: Coronavirus In Maryland, Tracking The Spread Latest coronavirus stories from WJZ Latest CDC Guidelines Researchers said following Dose 1, tenderness and pain were the most frequent local symptoms and systemic events were individually less frequent with headache, fatigue and myalgia being...
    Novavaxs COVID-19 vaccine study generated a promising immune response in an early-stage clinical trial in results unveiled Tuesday, reports The Wall Street Journal. The company has never brought a vaccine to market in its 33-year history but received a $1.6 billion grant from the governments Operation Warp Speed to have 100 million doses ready by early 2021. The phase one trial included 131 healthy participants between the ages of 18 and 59 at two sites in Australia. Novavax, of Maryland, said the vaccine was "well-tolerated and had a reassuring safety profile" and provoked an immune response with higher levels of antibodies in people who received the vaccine than in people who had recovered from coronavirus. Scientists mixed stable, prefusion protein...
    From the get-go with the coronavirus, experts have told us that what will save us is a vaccine. But a new poll published Tuesday reveals that a steadily decreasing share of Americans — significantly less than half — say they are willing to get the COVID-19 vaccine should one ever be developed, Yahoo News reported.What did people say about getting vaccinated? Polling by Yahoo News and YouGov have found fewer and fewer of us are planning to get a COVID vaccine once one is developed. When the surveys first began in early May, 55% of all Americans said they would get vaccinated. That number has shrunk every time the poll has been conducted. In late may,...
    Gaithersburg’s Novavax Inc. (NASDAQ: NVAX) reported Tuesday positive phase 1 clinical trial data on its Covid-19 vaccine candidate, a necessary step to advance a product that, officials hope will eventually protect people from the coronavirus. The study found the candidate, called NVX-CoV2373, to both be generally well-tolerated and elicit “robust antibody responses,” the company said Tuesday, adding that it showed the potential to reduce the disease’s transmission. Specifically, the candidate had a “reassuring” safety profile with the most common tenderness and pain at the injection site, and less frequent, systemic symptoms including headache, fatigue and myalgia. And there were no “severe” adverse reactions, the company said. The data demonstrate the candidate has “a robust immunogenicity profile,” said Dr. Gregory...
    The race is on to find a treatment that works to quash the coronavirus — as the deadly disease continues to spread across the globe. Here’s a list of the most promising treatments and potential vaccines for SARS-CoV-2, the virus that causes COVID-19. Remdesivir The experimental antiviral drug, made by Gilead Sciences, was the first to get emergency-use authorization from the US Food and Drug Administration. It was initially developed to treat Hepatitis C and RSV, a virus that can cause potentially serious respiratory infections, and works by stopping viruses from replicating by inserting itself into infected genes. Remdesivir was recently shown to have reduced the risk of death for severely ill coronavirus patients by 62 percent during a clinical...
    The debauchery of finding a new coronavirus vaccine is perhaps “the space race” of the 21st century. If in the middle of the last century space and conquering it was the challenge of the great powers, now it is to find a solution that ends the pandemic. And again, like half a century ago, Russia wants to leave its contenders behind: last week, the Kremlin announced that it would start a massive vaccination project against the coronavirus in October with an injection of which little is known and whose efficacy has already been confirmed. has been questioned by international experts. “The first coronavirus vaccine, developed by the Gamaleya Institute, has completed its clinical trials and documentation is now being prepared...
    The pharmaceutical company Moderna started the last, longest step in the process of testing its COVID-19 vaccine candidate at the end of July — a Phase 3 clinical trial. It’s an enormous undertaking: their goal is to recruit 30,000 people, inject some of them with an experimental vaccine and then follow each and every one of them to see how many contract the coronavirus and how many do not. This will take months, even with the federal government’s Operation Warp Speed compressing the timeline whenever possible. Those months may seem endless when over a thousand people are dying from COVID-19 each day in the United States. The process is long and intensive for a reason, though. Just because a...
    SAN ANTONIO – The international, months-long search for a COVID-19 vaccine seems to be entering the home stretch. Last week, the world’s largest coronavirus vaccine study started human trials, and the federal government’s ”Operation Warp Speed” vaccine program is working to deliver 300 million doses of a vaccine by January. The race for a coronavirus vaccine is vital to returning back to “normal.” Still, once a vaccine is proven safe and is widely available to the public across the world, it could still be months until restrictions such as masks and social distancing would be lifted, experts say. For an in-depth explanation of the search for a vaccine, watch this week’s episode of KSAT Explains available to stream on August...
    A patient from New York is given a flu shot by a Medical Assistant in New York.Timothy A. Clary | AFP | Getty Images Flu-shot manufacturers plan to ship record numbers of vaccine doses to the U.S. this year as public health officials prepare to urge as many Americans as possible to protect themselves amid the Covid-19 pandemic. "Though we don't yet have a vaccine for Covid, we do have a tool to prevent influenza," said Dr. Nancy Messonnier, director of the Centers for Disease Control and Prevention's National Center for Immunization and Respiratory Diseases, in a recent podcast interview. The four makers of flu vaccines have said they plan to ship almost 200 million doses to the U.S. this...
    By Lisandra Paraguassu, Pedro Fonseca and Eduardo Simões BRASILIA (Reuters) - Brazilian officials say they can start making COVID-19 vaccines developed by British and Chinese researchers within a year. Experts say it will take at least twice as long, leaving Brazil reliant on imports to slow the world's second-worst outbreak. If Brazil's underfunded medical institutions are unable to meet their ambitious goals, it would mark the latest failure by President Jair Bolsonaro's government to control the virus. It would also leave Brazil vulnerable to a frenzied global scramble for vaccine supplies. Some of the most advanced COVID-19 vaccine candidates - including from AstraZeneca Plc in partnership with Oxford University, and China's Sinovac Biotech Ltd - are undergoing large clinical trials...
    It was no routine shot in the arm.  Last week university professor Gary Stradiotto became one of 30,000 volunteers helping to test a vaccine in the world's biggest COVID-19 study. Stradiotto, 52, an adjunct professor of Political Science at the University of San Diego, volunteered for the final phase of the Moderna study and received his first 100mg of the experimental mRNA-1273 vaccine dose on Thursday.  He's due to get a second and final injection on August 26. Moderna's vaccine is one of several promising candidates in the final stretch of the global vaccine race, as the US tops more than 155,000 deaths and surpasses 4.6 million reported cases of the virus, according to government figures.  Stradiotto said he decided to volunteer...
    (CNN)Hydroxychloroquine is back! And this time it has brought not only hot-aired discussion but space aliens and demon sperm! Yes, it's true, the supposed miracle cure for Covid-19 that is really no cure at all, is all over the news again, thanks to President Donald Trump and a group of true believers, who are re-upping their endorsement of its all-around wonderfulness. Though distracting, the attention hydroxychloroquine is drawing raises a different but very important issue: whatever happened to the relentless US search for a Covid-19 cure? Kent SepkowitzRight now, we have three sort-of therapies for people with active infection, each with substantial limitations. Remdesivir is a new, expensive antiviral drug with modest benefit that must be given intravenously and is...
    Who gets to be first in line for a COVID-19 vaccine? US health authorities hope by late next month to have some draft guidance on how to ration initial doses, but it’s a vexing decision. “Not everybody’s going to like the answer,” Dr. Francis Collins, director of the National Institutes of Health, recently told one of the advisory groups the government asked to help decide. “There will be many people who feel that they should have been at the top of the list.” Traditionally, first in line for a scarce vaccine are health workers and the people most vulnerable to the targeted infection. But Collins tossed new ideas into the mix: Consider geography and give priority to people where an...
    Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, joined us ABC7 Eyewitness News Monday morning to discuss the latest developments in efforts to stop the spread of the coronavirus.We asked Dr. Fauci about Dr. Birx's recent comments that the U.S. is in a new phase of the virus and that it is extraordinarily widespread and the Moderna vaccineDr. Fauci also said it's a realistic timeline to have a vaccine available by the early part of next year.Watch the video above for the full interview.Who will be first in line for a COVID-19 vaccine?EMBED More News Videos Early-stage testing showed the first COVID-19 vaccine tested in the U.S. revved up people's immune systems the way scientists...
    Researchers are furiously working to create an effective vaccine against COVID-19. Top immunologists are hopeful that pharmaceutical companies can make a vaccine by the end of the year, but it will likely take months or even years to produce enough to protect billions of people across the globe. So the obvious question is: Who gets the vaccine first? “Not everybody’s going to like the answer,” Dr. Francis Collins, director of the National Institutes of Health, recently told one of the advisory groups the government asked to help decide, The Associated Press reports. “There will be many people who feel that they should have been at the top of the list.” It makes sense that health workers and those on the front...
    This article is reprinted by permission from NextAvenue.org. When Karen Tibbals of Washington, N.J. heard that more than 100,000 volunteers would be needed for late-stage clinical trials of four COVID-19 vaccines, she wanted to roll up her sleeves and get one of the experimental shots. Tibbals is 65 and has the autoimmune disease rheumatoid arthritis, raising her risk of suffering severe complications of COVID-19. But she also brings a unique perspective to the race to develop a vaccine: Tibbals is a retired pharmaceutical marketing executive who saw the clinical trial process up close during stints at Novartis NVS, -2.48% and Merck. MRK, +1.58% Some of the coronavirus vaccines entail delivering bits of genetic material from the virus to prompt the...
    HOLLYWOOD, Calif. (KABC) -- The Los Angeles Police Department is stepping up efforts to educate people about the importance of wearing a face covering.Officers handed out masks in Hollywood on Sunday.Residents, tourists, and even people driving along Hollywood Boulevard all expressed their appreciation."We're going to promote healthy living, healthy lifestyle, notify people, advise them of the reasons why to wear a mask, explain why it's going to be helpful, to help prevent spread of the disease," said Officer Eric Hale.The officers handed out about 300 masks, reminding everyone to take all of the precautions recommended by the CDC.Who will be first in line for a COVID-19 vaccine?EMBED More News Videos Early-stage testing showed the first COVID-19 vaccine tested in the...
    SAN FRANCISCO (KGO) -- A Pennsylvania school has found a creative way to keep classrooms sanitized: A virus-killing robot!The mobile disinfection robot was designed by "Safe Space Technologies."Its sole purpose is to disinfect large rooms like school cafeterias, gyms and other commercial businesses.The robot uses powerful UBC and UVC lights, which viruses like the coronavirus have no defense against.RELATED: Coronavirus impact: Here's how back-to-school shopping will look different amid pandemicThis can also help shorten disinfecting times."You could do two cafeterias and two gymnasiums in four hours, which would take a lot longer if you are using manpower," said Safe Space Technologies Marketing Director Chris Proud.Armed with an internal GPS system, it can be programmed and monitored remotely.The only downside --...
    Who gets to be first in line for a COVID-19 vaccine? U.S. health authorities hope by late next month to have some draft guidance on how to ration initial doses, but it's a vexing decision."Not everybody's going to like the answer," Dr. Francis Collins, director of the National Institutes of Health, recently told one of the advisory groups the government asked to help decide. "There will be many people who feel that they should have been at the top of the list."Traditionally, first in line for a scarce vaccine are health workers and the people most vulnerable to the targeted infection.But Collins tossed new ideas into the mix: Consider geography and give priority to people where an outbreak is hitting...
    Who gets to be first in line for a COVID-19 vaccine? U.S. health authorities hope by late next month to have some draft guidance on how to ration initial doses, but it's a vexing decision.   "Not everybody's going to like the answer," Dr. Francis Collins, director of the National Institutes of Health, recently told one of the advisory groups the government asked to help decide. "There will be many people who feel that they should have been at the top of the list."  Traditionally, first in line for a scarce vaccine are health workers and the people most vulnerable to the targeted infection.  But Collins tossed new ideas into the mix: Consider geography and give priority to people where...
    By LAURAN NEERGAARD, AP Medical Writer Who gets to be first in line for a COVID-19 vaccine? U.S. health authorities hope by late next month to have some draft guidance on how to ration initial doses, but it’s a vexing decision. “Not everybody’s going to like the answer,” Dr. Francis Collins, director of the National Institutes of Health, recently told one of the advisory groups the government asked to help decide. “There will be many people who feel that they should have been at the top of the list.” Traditionally, first in line for a scarce vaccine are health workers and the people most vulnerable to the targeted infection. But Collins tossed new ideas into the mix: Consider geography and...
    Who gets to be first in line for a COVID-19 vaccine? U.S. health authorities hope by late next month to have some draft guidance on how to ration initial doses, but it’s a vexing decision. “Not everybody’s going to like the answer,” Dr. Francis Collins, director of the National Institutes of Health, recently told one of the advisory groups the government asked to help decide. “There will be many people who feel that they should have been at the top of the list.” Traditionally, first in line for a scarce vaccine are health workers and the people most vulnerable to the targeted infection. But Collins tossed new ideas into the mix: Consider geography and give priority to people where...
    Science, as it is done in in most laboratories around the world, advances by careful steps. Medical science in particular can involve months or years of theoretical models, in-vitro testing, and animal trials before first first pill, procedure, or needle approaches a human being. But there’s another kind of science. The kind practiced by people who maybe empathized a little too closely with Robert Heinlein characters a little too closely in their youth. These people may occasionally produce great things despite being definitive assholes. And even in medical science, there seem to be plenty of people ready to try on the white lab coat of Rick Sanchez and get their mad on.  That seems to be the case with a group of researchers at MIT...
    MOSCOW – Clinical tests of the COVID-19 vaccine developed by Russia’s National Center for Epidemiological and Microbiological Research “Gamalei” have been completed and the registration phase is beginning, Russian Health Minister Mikhail Murashko reported. “The vaccine against the new coronavirus developed by the Gamalei center has completed clinical trials and documents are now being prepared for registration,” said Murashko, quoted by TASS. According to the Minister of Health, doctors and teachers will be the first to receive this vaccine, and it is planned that it will be sent to the Russian regions from August 10. “We plan to have the broader vaccination campaign, which will gradually be added to the new care system, begin in October,” he said. The...
    U.S. President Donald Trump delivers a speech during a visit to the Fujifilm Diosynth Biotechnologies' Innovation Center, a pharmaceutical manufacturing plant where components for a potential coronavirus disease (COVID-19) vaccine candidate are being developed, in Morrrisville, North Carolina, U.S., July 27, 2020.Carlos Barria | Reuters The hunt is on for a vaccine for Covid-19, which has killed more than 600,000 people. The current frontrunners include an mRNA vaccine from Moderna; a candidate vaccine from AstraZeneca and Oxford University; a Chinese vaccine from the military and biotech company CanSigo Biologisc; and an mRNA-based vaccine from German company BioNTech and Pfizer. While a candidate could be approved this year, it remains to be seen whether the vaccine will confer temporary or long-term...
    MOSCOW – Clinical tests of the COVID-19 vaccine developed by Russia’s National Center for Epidemiological and Microbiological Research “Gamalei” have been completed and the registration phase is beginning, Russian Health Minister Mikhail Murashko reported. “The vaccine against the new coronavirus developed by the Gamalei center has completed clinical trials and documents are now being prepared for registration,” said Murashko, quoted by TASS. According to the Minister of Health, doctors and teachers will be the first to receive this vaccine, and it is planned that it will be sent to the Russian regions from August 10. “We plan to have the broader vaccination campaign, which will gradually be added to the new care system, begin in October,” he said. The...
    MOSCOW – Clinical tests of the COVID-19 vaccine developed by Russia’s National Center for Epidemiological and Microbiological Research “Gamalei” have been completed and the registration phase is beginning, Russian Health Minister Mikhail Murashko reported. “The vaccine against the new coronavirus developed by the Gamalei center has completed clinical trials and documents are now being prepared for registration,” said Murashko, quoted by TASS. According to the Minister of Health, doctors and teachers will be the first to receive this vaccine, and it is planned that it will be sent to the Russian regions from August 10. “We plan to have the broader vaccination campaign, which will gradually be added to the new care system, begin in October,” he said. The...
    By Michael Erman and Carl O’Donnell Jul 31 (.) – The US government will pay $ 2.1 billion to Sanofi SA and GlaxoSmithKline Plc for their COVID-19 vaccines to cover 50 million people and ensure testing and production, the companies said on Friday. . Drug makers also announced that they are in advanced talks to supply up to 300 million doses of the experimental vaccine to the European Union. The agreement is the largest signed by the United States in the framework of “Operation Speed ​​Warp”, the White House initiative aimed at accelerating access to vaccines and treatments to combat COVID-19, the respiratory disease caused by the new coronavirus. The treatment announced by the Department of Health and Human Services...
    Former Vice President Joe Biden on Tuesday during a campaign speech appeared to be unaware of the Trump administration’s ongoing efforts to combat the coronavirus, at one point suggesting that President Trump do something that he is already doing. Biden said that Trump should have started three months ago to put someone in charge of how to distribute a vaccine for COVID-19 when it is ready — something that Trump did three months ago. Biden said (emphasis added): But I want to say it again, I’m going to keep saying it. The president, as we speak, should be starting and should have started three months ago to put someone in charge of how specifically, like waging a war. How are you...
    On Friday morning,  leading infectious disease expert Dr. Anthony Fauci and other members of the White House coronavirus task force testified before a House subcommittee on the Trump administration’s coronavirus response. The hearing took place as more than 150,000 lives have been lost to the novel coronavirus and the country leads the world in total cases with over 4 million Americans infected. Despite these grim numbers, some states continue to reopen, and many are planning on sending kids back to school this fall. The piecemeal approach to control the virus in the U.S. has been scrutinized and the subject of debate, especially as other countries have seemingly managed to control its spread and lower the number of infections. Fauci, Dr. Robert Redfield, director of the...
    As medical professionals continue to work on a COVID-19 vaccine, one group is looking for adults of all races, ethnic groups, sexes and genders to volunteer for a clinical trial.It does not matter if you're not in perfect health because researchers with the COVID-19 Prevention Network want to see how the vaccine affects people with underlying health conditions.It's important to note that the vaccine trial will require a significant time commitment.Participants will have to visit a research site up to a dozen times and keep track of how they feel after receiving a shot.Those over the age of 18 interested in volunteering can visit the COVID-19 Prevention Network website to fill out a survey and see if they qualify for...
    By RICARDO ALONSO-ZALDIVAR and MATTHEW PERRONE WASHINGTON (AP) — Once a coronavirus vaccine is approved as safe and effective, Americans should have widespread access within a reasonable time, Dr. Anthony Fauci assured lawmakers Friday. Appearing before a House panel investigating the nation’s response to the pandemic, Fauci expressed “cautious” optimism that a vaccine would be available, particularly by next year. “I believe, ultimately, over a period of time in 2021, that Americans will be able to get it,” Fauci said, referring to the vaccine. There will be a priority list for who gets early vaccinations. “I don’t think we will have everybody getting it immediately,” Fauci explained. But “ultimately, within a reasonable time, the plans allow for any American who...
     Presented by Facebook  To view past editions of The Hill's 12:30 Report, click here: http://bit.ly/1M1mIfw  To receive The Hill's 12:30 Report in your inbox, please sign up here: http://bit.ly/1Tt4hqN --> A midday take on what's happening in politics and how to have a sense of humor about it.* *Ha. Haha. Hahah. Sniff. Haha. Sniff. Ha--breaks down crying hysterically.   The Hill’s 12:30 Report: Fauci testifies | Says he’s ‘Cautiously optimistic’ about a vaccine by end of the year | Says 250+ have signed up for clinical trials | 6 MLB teams no longer playing today | $600 unemployment benefit expires at midnight | Duckworth in the running for Biden VP | National Avocado Day   ON CAPITOL HILL Anthony FauciAnthony FauciTrump says he can't assure school safety amid pandemic: 'Can you...
    Once a coronavirus vaccine is approved as safe and effective, Americans should have widespread access within a reasonable time, Dr. Anthony Fauci assured lawmakers Friday. Appearing before a House panel investigating the nations response to the pandemic, Fauci expressed “cautious” optimism that a vaccine would be available, particularly by next year. “I believe, ultimately, over a period of time in 2021, that Americans will be able to get it,” Fauci said, referring to the vaccine. There will be a priority list for who gets early vaccinations. “I dont think we will have everybody getting it immediately,” Fauci explained. But “ultimately, within a reasonable time, the plans allow for any American who needs the vaccine to get it,” he added. Under...
    Chinese government-linked hackers targeted a US based coronavirus vaccine research developer this year in an attempt to steal data, according to a US security official tracking Chinese hacking. On Friday, China rejected the accusations that the hackers that targeted Moderna Inc, were linked to their government. 3China rejected the allegations that Chinese government-linked hackers targeted a US based coronavirus vaccine research developer, Moderna IncCredit: Reuters Last week, the US Justice made public an indictment of two Chinese nationals accused of spying on the United States. The July 7 indictment alleges that that two Chinese hackers, identified as Li Xiaoyu and Dong Jiazhi, conducted a decade-long hacking spree that most recently included the targeting of COVID-19 medical research groups. The surveillance...
    The feds will give Sanofi and GlaxoSmithKline as much as $2.1 billion to churn out a coronavirus vaccine within the Trump administration’s newest and largest guess on an experimental inoculation. Greater than half the award introduced Friday will assist the European drugmakers develop and take a look at their vaccine, whereas the remaining can be used to help manufacturing and ship 100 million doses, the businesses stated. The deal — a part of the US’s Operation Warp Velocity — offers the feds the choice to amass 500 million further doses assuming the vaccine proves protected and efficient in medical research which have but to start. “We thank the US authorities for enjoying a vital function in offering early, important...
    The feds will give Sanofi and GlaxoSmithKline up to $2.1 billion to churn out a coronavirus vaccine in the Trump administration’s latest and largest bet on an experimental inoculation. More than half the award announced Friday will help the European drugmakers develop and test their vaccine, while the rest will be used to support manufacturing and deliver 100 million doses, the companies said. The deal — part of the US’s Operation Warp Speed — gives the feds the option to acquire 500 million additional doses assuming the vaccine proves safe and effective in clinical studies that have yet to begin. “We thank the US government for playing a very important role in providing early, significant funding to enable the development...